Asset Details
Do you wish to reserve the book?
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Do you wish to request the book?
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
2020
Overview
Patients with chronic heart failure and a reduced ejection fraction were randomly assigned to the soluble guanylate cyclase stimulator vericiguat or placebo, in addition to guideline-based medical therapy. The incidence of death from cardiovascular causes or first hospitalization for heart failure was lower among patients who received vericiguat.
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Cardiology and cardiovascular system
/ Cardiovascular Diseases - mortality
/ Death
/ Female
/ Heart Failure - drug therapy
/ Heart Failure - physiopathology
/ Heterocyclic Compounds, 2-Ring - adverse effects
/ Heterocyclic Compounds, 2-Ring - therapeutic use
/ Hospitalization - statistics & numerical data
/ Humans
/ Hypotension - chemically induced
/ Male
/ Peptides
/ Pyrimidines - adverse effects
/ Pyrimidines - therapeutic use
/ Soluble Guanylyl Cyclase - metabolism
/ Syncope
